![](/img/cover-not-exists.png)
Characterization of haematological parameters with bortezomib–melphalan–prednisone versus melphalan–prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial
Paul Richardson, Rudolf Schlag, Nuriet Khuageva, Meletios Dimopoulos, Ofer Shpilberg, Martin Kropff, Marie-Christiane Vekemans, Maria Teresa Petrucci, Viktor Rossiev, Jian Hou, Tadeusz Robak, Maria-ViVolume:
153
Year:
2011
Language:
english
Pages:
10
DOI:
10.1111/j.1365-2141.2011.08569.x
File:
PDF, 184 KB
english, 2011